Limits...
Abatacept in the treatment of rheumatoid arthritis.

Vital EM, Emery P - Ther Clin Risk Manag (2006)

Bottom Line: Abatacept (CTLA4-Ig) is a new agent which targets T-cell activation, an event which is thought to be critical to the onset and maintenance of rheumatoid arthritis (RA).Safety profile is favorable in combination with DMARDs.The mechanism of action and available evidence of its efficacy and safety are reviewed in this article.

View Article: PubMed Central - PubMed

Affiliation: Academic Unit of Musculoskeletal Disease, University of Leeds, Chapel Allerton Hospital Leeds, UK.

ABSTRACT
Abatacept (CTLA4-Ig) is a new agent which targets T-cell activation, an event which is thought to be critical to the onset and maintenance of rheumatoid arthritis (RA). Abatacept now has substantial evidence from phase III trials for efficacy in patients with RA who have failed to respond to disease-modifying antirheumatic drugs (DMARDs) and antitumor necrosis factor-alpha (TNF-alpha) biologic agents. Safety profile is favorable in combination with DMARDs. The mechanism of action and available evidence of its efficacy and safety are reviewed in this article.

No MeSH data available.


Related in: MedlinePlus

ACR improvements in disease activity in the ATTAIN trial at 6 months.Abbreviations: ACR, American College of Rheumatology; ATTAIN, Abatacept trial in treatment of anti-tumor necrosis factor inadequate responders; DAS, diseaseactivity scores.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC1936358&req=5

fig5: ACR improvements in disease activity in the ATTAIN trial at 6 months.Abbreviations: ACR, American College of Rheumatology; ATTAIN, Abatacept trial in treatment of anti-tumor necrosis factor inadequate responders; DAS, diseaseactivity scores.

Mentions: There were significant improvements in all of the primary and secondary endpoints at six months. Data for improvements in the components of the ACR and DAS28 response have been published separately. These data are summarized in Figure 5 and Table 4. These response rates are impressive for such a resistant group of patients, including an ACR20 rate of 50.4% and a DAS28 remission rate of 10.0%. mHAQ improved in 47.3% of patients in the abatacept arm compared with 23.3% on placebo. Mean mHAQ disability index improvement from baseline was 0.45 for abatacept compared with 0.11 for placebo. Of 34 discontinuations in the placebo arm, 27 were due to lack of efficacy and 5 due to adverse events. In the abatacept arm, 14 discontinued due to lack of efficacy and 9 due to adverse events.


Abatacept in the treatment of rheumatoid arthritis.

Vital EM, Emery P - Ther Clin Risk Manag (2006)

ACR improvements in disease activity in the ATTAIN trial at 6 months.Abbreviations: ACR, American College of Rheumatology; ATTAIN, Abatacept trial in treatment of anti-tumor necrosis factor inadequate responders; DAS, diseaseactivity scores.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC1936358&req=5

fig5: ACR improvements in disease activity in the ATTAIN trial at 6 months.Abbreviations: ACR, American College of Rheumatology; ATTAIN, Abatacept trial in treatment of anti-tumor necrosis factor inadequate responders; DAS, diseaseactivity scores.
Mentions: There were significant improvements in all of the primary and secondary endpoints at six months. Data for improvements in the components of the ACR and DAS28 response have been published separately. These data are summarized in Figure 5 and Table 4. These response rates are impressive for such a resistant group of patients, including an ACR20 rate of 50.4% and a DAS28 remission rate of 10.0%. mHAQ improved in 47.3% of patients in the abatacept arm compared with 23.3% on placebo. Mean mHAQ disability index improvement from baseline was 0.45 for abatacept compared with 0.11 for placebo. Of 34 discontinuations in the placebo arm, 27 were due to lack of efficacy and 5 due to adverse events. In the abatacept arm, 14 discontinued due to lack of efficacy and 9 due to adverse events.

Bottom Line: Abatacept (CTLA4-Ig) is a new agent which targets T-cell activation, an event which is thought to be critical to the onset and maintenance of rheumatoid arthritis (RA).Safety profile is favorable in combination with DMARDs.The mechanism of action and available evidence of its efficacy and safety are reviewed in this article.

View Article: PubMed Central - PubMed

Affiliation: Academic Unit of Musculoskeletal Disease, University of Leeds, Chapel Allerton Hospital Leeds, UK.

ABSTRACT
Abatacept (CTLA4-Ig) is a new agent which targets T-cell activation, an event which is thought to be critical to the onset and maintenance of rheumatoid arthritis (RA). Abatacept now has substantial evidence from phase III trials for efficacy in patients with RA who have failed to respond to disease-modifying antirheumatic drugs (DMARDs) and antitumor necrosis factor-alpha (TNF-alpha) biologic agents. Safety profile is favorable in combination with DMARDs. The mechanism of action and available evidence of its efficacy and safety are reviewed in this article.

No MeSH data available.


Related in: MedlinePlus